GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop
Authors
Keywords
-
Journal
Journal of Parkinsons Disease
Volume -, Issue -, Pages 1-17
Publisher
IOS Press
Online
2020-06-03
DOI
10.3233/jpd-202004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease
- (2019) Alan L. Whone et al. Journal of Parkinsons Disease
- Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease
- (2019) Alan Whone et al. BRAIN
- Magnetic Resonance Imaging–Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease
- (2019) Chadwick W. Christine et al. ANNALS OF NEUROLOGY
- CDNF Protein Therapy in Parkinson’s Disease
- (2019) Henri J. Huttunen et al. CELL TRANSPLANTATION
- Trial of magnetic resonance–guided putaminal gene therapy for advanced Parkinson's disease
- (2019) John D. Heiss et al. MOVEMENT DISORDERS
- Glial cell line–derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo
- (2019) Arun Kumar Mahato et al. MOVEMENT DISORDERS
- The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinson’s disease
- (2018) Petra Tomše et al. Physica Medica-European Journal of Medical Physics
- Trophic factors for Parkinson's disease: Where are we and where do we go from here?
- (2018) Gesine Paul et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models
- (2017) Xiaomin Su et al. MOLECULAR THERAPY
- Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
- (2016) Ganqiang Liu et al. ANNALS OF NEUROLOGY
- AAV viral vector delivery to the brain by shape-conforming MR-guided infusions
- (2016) Krystof S. Bankiewicz et al. JOURNAL OF CONTROLLED RELEASE
- Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease
- (2016) Pia Runeberg-Roos et al. NEUROBIOLOGY OF DISEASE
- Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
- (2015) C. Warren Olanow et al. ANNALS OF NEUROLOGY
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies
- (2015) R.T. Bartus et al. NEUROBIOLOGY OF DISEASE
- 18F-DOPA, a Clinically Available PET Tracer to Study Brain Inflammation?
- (2014) Quentin Sala et al. CLINICAL NUCLEAR MEDICINE
- Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort
- (2013) Sophie E. Winder-Rhodes et al. BRAIN
- Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease
- (2013) Jeffrey H. Kordower et al. BRAIN
- Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF
- (2013) A. P. Kells et al. JOURNAL OF NEUROSCIENCE
- Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation
- (2013) N. K. Patel et al. NEUROLOGY
- Axonal transport of adeno-associated viral vectors is serotype-dependent
- (2012) E A Salegio et al. GENE THERAPY
- -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
- (2012) M. Decressac et al. Science Translational Medicine
- GDNF fails to exert neuroprotection in a rat -synuclein model of Parkinson's disease
- (2011) M. Decressac et al. BRAIN
- Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin
- (2011) Maxim M. Bespalov et al. JOURNAL OF CELL BIOLOGY
- Glial-derived neurotrophic factor gene transfer for Parkinson's disease: Anterograde distribution of AAV2 vectors in the primate brain
- (2011) Adrian P. Kells et al. NEUROBIOLOGY OF DISEASE
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
- (2010) William J Marks et al. LANCET NEUROLOGY
- Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons
- (2009) Marjo Piltonen et al. EXPERIMENTAL NEUROLOGY
- Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys
- (2009) Jamie L. Eberling et al. HUMAN GENE THERAPY
- Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
- (2008) William J Marks et al. LANCET NEUROLOGY
- Real-time MR imaging of adeno-associated viral vector delivery to the primate brain
- (2008) Massimo S. Fiandaca et al. NEUROIMAGE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now